1800-272-662
Shopping Cart 0
countryflagAU
Login

Arcturus Therapeutics Holdings Inc

Healthcare US ARCT

7.47USD
-0.15(1.97%)

Last update at 2026-03-11T15:05:00Z

Day Range

7.367.73
LowHigh

52 Week Range

14.9345.00
LowHigh

Fundamentals

  • Previous Close 7.62
  • Market Cap497.32M
  • Volume210031
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-77.00700M
  • Revenue TTM160.40M
  • Revenue Per Share TTM5.96
  • Gross Profit TTM 62.95M
  • Diluted EPS TTM-2.33

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax 10.64M -203.67400M -72.14800M -25.99100M -21.78500M
Minority interest - - - - -
Net income 9.35M -206.86300M -71.36400M -25.72100M -21.78500M
Selling general administrative 46.07M 41.45M 23.22M 12.66M 20.58M
Selling and marketing expenses - - - - -
Gross profit 205.75M 12.36M 9.54M 20.79M 15.75M
Reconciled depreciation 1.53M 1.19M 0.88M 0.68M 0.58M
Ebit 12.18M -202.85200M -71.52400M -25.51300M -21.59900M
Ebitda 11.66M -200.39100M -71.78700M -25.54500M -21.01700M
Depreciation and amortization -0.51500M 2.46M -0.26300M -0.03200M 0.58M
Non operating income net other - -0.82200M -0.62400M -0.47800M -
Operating income 12.18M -202.85200M -71.52400M -25.51300M -21.81100M
Other operating expenses 193.58M 215.21M 81.06M 46.30M 37.56M
Interest expense 0.42M 2.67M 0.36M 0.45M 0.19M
Tax provision 1.29M - - - 0.00000M
Interest income 2.58M 0.75M 0.47M 0.41M 0.51M
Net interest income -0.42000M -1.92100M -0.36100M -0.44600M 0.33M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 1.29M 3.19M -0.78400M -0.27000M 0.21M
Total revenue 205.75M 12.36M 9.54M 20.79M 15.75M
Total operating expenses 193.58M 215.21M 81.06M 46.30M 37.56M
Cost of revenue - - - 33.64M 16.98M
Total other income expense net -1.53300M -0.82200M -0.62400M -0.47800M -0.30200M
Discontinued operations - - - - -
Net income from continuing ops 9.35M -203.67400M -72.14800M -25.99100M -21.78500M
Net income applicable to common shares 9.35M -203.67400M -72.14800M -25.99100M -21.78500M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 429.40M 450.39M 392.81M 476.46M 82.14M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 7.52M 8.69M 5.10M 2.77M 0.76M
Total liab 150.89M 180.07M 164.60M 79.90M 56.35M
Total stockholder equity 278.51M 270.31M 228.21M 396.55M 25.79M
Deferred long term liab - - 19.93M 12.51M 15.18M
Other current liab 25.06M 30.23M 23.52M 17.76M 6.31M
Common stock 0.03M 0.03M 0.03M 0.03M 0.01M
Capital stock 0.03M 0.03M 0.03M 0.03M 0.01M
Retained earnings -367.86600M -338.14100M -347.49000M -143.81600M -71.66800M
Other liab - 22.88M 19.93M 12.51M 15.18M
Good will - - - - -
Other assets - - 2.08M 5.29M 0.11M
Cash 347.00M 391.88M 370.49M 462.89M 71.35M
Cash and equivalents - - - - -
Total current liabilities 81.99M 126.98M 99.54M 49.52M 21.32M
Current deferred revenue 47.34M 28.65M 43.48M 18.11M 8.40M
Net debt -316.78900M -301.01200M -302.88300M -445.02500M -51.50800M
Short term debt 4.31M 60.66M 22.47M 2.88M 0.83M
Short long term debt - 60.66M 22.47M 1.25M -
Short long term debt total 30.22M 90.87M 67.61M 17.87M 19.84M
Other stockholder equity 646.35M 608.43M 575.67M 540.34M 97.44M
Property plant equipment - 44.96M 11.26M 3.38M 7.48M
Total current assets 386.59M 403.33M 378.96M 467.79M 74.29M
Long term investments - 0.00000M 0.52M 0.00000M 0.26M
Net tangible assets - - 228.21M 396.55M 25.79M
Short term investments - - - - -
Net receivables 32.06M 2.76M 3.37M 2.12M 2.18M
Long term debt - - 40.63M 13.85M 14.99M
Inventory 0.00000M - - - -
Accounts payable 5.28M 7.45M 10.06M 10.77M 5.79M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - - -2.18100M
Additional paid in capital - - - - -
Common stock total equity - - 0.03M 0.03M 0.01M
Preferred stock total equity - - - - -
Retained earnings total equity - - -347.49000M -143.81600M -71.66800M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 1.89M 2.09M 2.08M 0.11M 0.11M
Deferred long term asset charges - - - - -
Non current assets total 42.81M 47.05M 13.85M 8.67M 7.85M
Capital lease obligations 30.22M 34.10M 6.04M 5.66M 5.68M
Long term debt total - - 40.63M 13.85M 14.99M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -7.72600M -3.40600M -1.74200M -0.81800M 22.13M
Change to liabilities 0.00000M 32.02M 16.13M 4.83M 0.74M
Total cashflows from investing activities -7.72600M -3.40600M -1.74200M -0.81800M 22.13M
Net borrowings -5.00000M 46.60M 46.60M 4.95M 9.87M
Total cash from financing activities -2.85900M 48.02M 436.14M 41.91M 10.20M
Change to operating activities - 0.45M 9.31M 1.55M 2.11M
Net income 9.35M -203.67400M -72.14800M -25.99100M -21.78500M
Change in cash 21.41M -90.43300M 391.54M 34.64M 11.58M
Begin period cash flow 372.57M 463.00M 71.46M 36.82M 25.24M
End period cash flow 393.98M 372.57M 463.00M 71.46M 36.82M
Total cash from operating activities 31.99M -135.04300M -42.86100M -6.44500M -20.76000M
Issuance of capital stock 0.41M 0.52M 423.82M 36.82M 0.00000M
Depreciation 1.53M 1.19M 0.88M 0.68M 0.58M
Other cashflows from investing activities - - - - 23.61M
Dividends paid - - - - -
Change to inventory - 0.45M 9.31M 1.55M 2.11M
Change to account receivables 0.60M -1.24200M 0.05M 2.30M -4.00100M
Sale purchase of stock - 1.42M 426.55M 36.96M 0.33M
Other cashflows from financing activities 1.73M 47.50M 12.33M 5.08M 10.20M
Change to netincome - 36.20M 6.76M 2.85M 1.60M
Capital expenditures 7.73M 3.41M 1.74M 0.82M 1.48M
Change receivables - -1.24200M 0.05M 2.30M -
Cash flows other operating - 29.95M 5.46M 8.88M -
Exchange rate changes - - - - -
Cash and cash equivalents changes - -90.43300M 391.54M 34.64M -
Change in working capital -12.55700M 31.23M 21.22M 15.98M -1.15600M
Stock based compensation 30.61M 28.91M 6.76M 1.98M 1.26M
Other non cash items 3.06M 8.38M 0.16M 0.87M 0.04M
Free cash flow 24.27M -138.44900M -44.60300M -7.26300M -22.23800M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
ARCT
Arcturus Therapeutics Holdings Inc		 -0.15 1.97% 7.47 - 2.48 3.10 1.95 2.12 -25.6651
NVO
Novo Nordisk A/S		 0.16 0.41% 38.88 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 0.005 0.01% 38.74 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -4.89 0.98% 494.28 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 3.71 0.48% 775.75 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

Arcturus Therapeutics Holdings Inc

10628 Science Center Drive, San Diego, CA, United States, 92121

Key Executives

Name Title Year Born
Mr. Joseph E. Payne M.Sc. Founder, Pres, CEO & Director 1972
Dr. Padmanabh Chivukula Founder, Chief Scientific Officer, COO & Sec. 1979
Mr. Andrew H. Sassine MBA CFO & Director 1964
Mr. Lance Kurata Chief Legal Officer NA
Dr. Steven George Hughes M.B.A., M.D. Strategic Clinical Advisor & Member of Scientific Advisory Board 1968
Mr. Keith C. Kummerfeld CPA VP of Fin. & Corp. Controller NA
Dr. Dushyant B. Varshney Ph.D. Exec. VP & Chief Technology Officer NA
Mr. Deepankar Roy Sr. Director of Investor Relations NA
Kyle Gutstadt Sr. Analyst of Investor & PR NA
Mr. Kevin T. Skol Sr. VP of Bus. Devel. & Alliance Management NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.